Latest News

Meet the iOnctura team at the following events:

iOnctura exercises exclusive global option to license two of Cancer Research UK’s projects

iOnctura SA is delighted to announce today that it has exercised its exclusive global option to license two of Cancer Research UK’s projects, which are the result of a successful strategic alliance programme with CRUK-Therapeutic Discovery Labs (TDL). Under the terms of the licence agreements iOnctura will be solely responsible for the development and commercialisation … Continue reading “iOnctura exercises exclusive global option to license two of Cancer Research UK’s projects”

iOnctura Expands its Clinical Advisory Board

Geneva, Switzerland, 4th February 2020: iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces the addition of new members to its Clinical Advisory Board (CAB) with the appointment of Dr. Hendrik-Tobias Arkenau, Executive Medical Director, Sarah Cannon Research Institute, UK, and Dr. Jordi Rodón Ahnert, … Continue reading “iOnctura Expands its Clinical Advisory Board”

iOnctura raises EUR 15 million in Series A financing to progress its pipeline into clinical development

Amsterdam, The Netherlands, January 23, 2020: iOnctura B.V., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces today the closing of a EUR 15 million Series A financing. The financing was led by INKEF Capital and co-led by VI Partners with participation by new investor Schroder Adveq. … Continue reading “iOnctura raises EUR 15 million in Series A financing to progress its pipeline into clinical development”

By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.

GET IN TOUCH